Jonathan Chang
Stock Analyst at Leerink Partners
(0.66)
# 3,760
Out of 4,827 analysts
86
Total ratings
30.14%
Success rate
-19.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Upgrades: Outperform | $27 | $19.42 | +39.03% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $29.79 | +148.41% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $3.35 | +228.36% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $17.44 | +192.43% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $6.15 | +1,119.51% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $7.77 | +337.58% | 9 | Dec 7, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $8.18 | +511.25% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $41.91 | -28.42% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.54 | +679.22% | 8 | Aug 9, 2022 | |
| MRSN Mersana Therapeutics | Maintains: Outperform | $13 → $14 | $0.34 | +4,079.10% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $4.34 | +499.08% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $29.14 | +226.01% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.30 | +900.00% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $6.00 | +366.67% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $8.79 | +502.96% | 7 | Aug 5, 2021 |
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $19.42
Upside: +39.03%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $29.79
Upside: +148.41%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $3.35
Upside: +228.36%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $17.44
Upside: +192.43%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $6.15
Upside: +1,119.51%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $7.77
Upside: +337.58%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $8.18
Upside: +511.25%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $41.91
Upside: -28.42%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.54
Upside: +679.22%
Mersana Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $0.34
Upside: +4,079.10%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $4.34
Upside: +499.08%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $29.14
Upside: +226.01%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.30
Upside: +900.00%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $6.00
Upside: +366.67%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $8.79
Upside: +502.96%